HF
CBIO

HRT Financial’s Crescent Biopharma CBIO Stock Holding History

HRT Financial’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,083
Closed -$155K – 4135
2025
Q4 		$155K Buy
+13,083
New +$167K ﹤0.01% 2695
2025
Q2 		– Sell
-100
Closed -$2K – 2970
2025
Q1 		$2K Buy
+100
New +$2.68K ﹤0.01% 2427
2024
Q4 		– Sell
-323
Closed -$5K – 2697
2024
Q3 		$5K Sell
323
-154
-32% -$3.23K ﹤0.01% 2267
2024
Q2 		$13K Sell
477
-1,081
-69% -$112K ﹤0.01% 1975
2024
Q1 		$467K Buy
+1,558
New +$465K ﹤0.01% 1297
2021
Q4 		– Sell
-513
Closed -$112K – 3511
2021
Q3 		$112K Sell
513
-568
-53% -$120K ﹤0.01% 2868
2021
Q2 		$250K Buy
+1,081
New +$275K ﹤0.01% 2263
2020
Q1 		– Sell
-399
Closed -$211K – 971
2019
Q4 		$211K Buy
399
+191
+92% +$103K 0.01% 920
2019
Q3 		$89K Buy
+208
New +$134K ﹤0.01% 1254

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial's CBIO Position: Q1 2026 in Review

HRT Financial sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 13,083 shares — an estimated $155K sold.

HRT Financial first reported a position in CBIO in Q3 2019 and held it in 9 quarters. The position peaked at $467K in Q1 2024. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • HRT Financial reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 13,083 Crescent Biopharma shares in Q1 2026, an estimated $155K.
  • HRT Financial first reported a position in Crescent Biopharma in Q3 2019 and held it in 9 quarters.
  • HRT Financial's Crescent Biopharma position peaked at $467K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.